Table 1 Demographic details of patients and treatment
From: OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients
Sex | Age at treatment (years) | Duration of HC at treatment (years) | Phenotype of HC | Indomethacin dose required to suppress HC | Co-existent headache | Previous number of treatments trialled | Reasons for administering BoNT-A | No of sessions of BoNT-A treatments | Average units injected | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Location | Autonomic symptoms * | Migrainous symptoms Ŧ | ||||||||||
1 | M | 19 | 1 | Right | Yes | Nil | 225 mg daily | EMWOA (Bilateral) | 4 | Worsening EM on Indometacin | 4 | 168 |
2 | F | 61 | 1 | Left | Yes | Yes Visual Aura | 150 mg daily | Nil | 4 | GI-upset | 3 | 165 |
3 | M | 59 | 12 | Right | Yes | Nil | IM Indometacin test** | Nil | 13 | Unable tolerate Indometacin; Refractory to other treatments; ONS in-situ | 2 | 175 |
4 | M | 48 | 2 | Right | Yes | Yes Visual Aura (occasional) | 150 mg daily | EMWA (bilateral, once month) | 9 | GI-upset; peptic ulcer disease; refractory to other treatments - awaiting ONS | 2 | 165 |
5 | F | 47 | 9 | Right | Yes | Yes | 225 mg daily | Past EMWOA (stopped 2004) | 3 | GI-upset | 5 | 167 |
6 | F | 49 | 34 | Right | Yes | Yes | 150 mg daily | EMWA (bilateral, once month) | 6 | GI-upset; refractory to other treatments; ONS in-situ | 2 | 110 |
7 | F | 48 | 18 | Left | Yes | Yes | IM Indometacin test** | ISH | 13 | GI-upset | 2 | 155 |
8 | F | 41 | 8 | Right | Yes | No Visual Aura | 150 mg daily | EMWOA (side variable/bilateral) | 7 | GI-upset; wheeze; dizziness; worsening EM | 6 | 168 |
9 | F | 54 | 4 | Right | Yes | Yes | 225 mg daily | Nil | 9 | GI-upset | 2 | 185 |
Mean | 47 | 10 | 8 | 3 | 162 | |||||||
Median (Range) | 48 (19–61) | 8 (1–34) | 7 (3-13) | 2 (2-6) | 167 (110–185) | |||||||